Hyperplasia

Pulse Biosciences has announced it received FDA 510(k) clearance for expanding the use of its CellFX System to treat sebaceous hyperplasia in patients with Fitzpatrick skin types I to III, according to a company press release.

Use of an external saphenous vein graft support device did not improve intimal hyperplasia area in patients undergoing CABG compared with an unsupported graft, according to results from the VEST trial.

In heart transplant recipients, PCSK9 inhibitors lowered LDL, stabilized coronary intimal hyperplasia and were associated with minimal adverse effects, according to data from the virtual Heart Failure Society of America Scientific Meeting.